EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Jan H Frenking iD, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder iD, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N Gezer und 21 weitere

HemaSphere · 2025-04 · 9 (4)

DOI: 10.1002/hem3.70114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 17.04.2025. Verfasst von Jan H Frenking und 32 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg Myeloma Center, Department of Medicine V University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific T‐cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL‐1 trial and was recently approved by the Food and Drug Administration and the European Medicines Agency. However, treatment under real‐world conditions may not represent patient characteristics in clinical trials with restricted enrollment criteria. We performed a retrospective real‐world analysis including 138 RRMM patients treated with talquetamab at 21 German centers. Of evaluable patients, 43% had ISS stage III, 37% had extraosseous disease, and 48% had high‐risk cytogenetics. After a median of six prior therapy lines, 58% of patients would not have been eligible for MonumenTAL‐1. With a median follow‐up of 8.2 months, we observed an overall response rate of 65% and a median progression‐free survival of 6.4 months (95% confidence interval 5.1–9.0). Prior BTCE exposure, ISS stage III, extraosseous disease, and penta‐drug refractory disease were associated with unfavorable outcomes. Grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 5.1% and 1.5% of patients, respectively. In summary, our real‐world study confirms the efficacy and safety of talquetamab, despite a high proportion of patient‐ and disease‐related risk factors. These results support its use as bridging or long‐term treatment, even in advanced stages.

Autor:innen und Institutionen

  • Heidelberg Myeloma Center, Department of Medicine V University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.
  • Clinical Cooperation Unit Molecular Hematology/Oncology German Cancer Research Center (DKFZ) Heidelberg Germany.
  • Department of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
  • Department of Internal Medicine I University Hospital Carl Gustav Carus Dresden Dresden Germany.
  • Internal Medicine III TUM University Hospital Technical University of Munich München Germany.
  • TranslaTUM Center for Translational Cancer Research Technical University of Munich München Germany.

ORCID-Profile: Jan H Frenking, Moritz Bewarder, Christine Hanoun, Igor Kos, Maximilian Merz

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Krebshilfe

Zitieren

APA

Frenking, J. H., Riedhammer, C., Teipel, R., Bassermann, F., Besemer, B., Bewarder, M., Braune, J., Brioli, A., Brunner, F., Dampmann, M., Fenk, R., Gezer, D. N., Goldman-Mazur, S., Hanoun, C., Högner, M., Khandanpour, C., Kolditz, K., Kos, I., Krönke, J., …, & Raab, M. S. (2025). A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma. HemaSphere, 9(4). https://doi.org/10.1002/hem3.70114

Vancouver

Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, et al. A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma. HemaSphere. 2025;9(4). doi:10.1002/hem3.70114

BibTeX
@article{Frenking2025,
  author = {Frenking, Jan H and Riedhammer, Christine and Teipel, Raphael and Bassermann, Florian and Besemer, Britta and Bewarder, Moritz and Braune, Jan and Brioli, Annamaria and Brunner, Franziska and Dampmann, Maria and Fenk, Roland and Gezer, Deniz N and Goldman-Mazur, Sarah and Hanoun, Christine and Högner, Marion and Khandanpour, Cyrus and Kolditz, Katja and Kos, Igor and Krönke, Jan and Kull, Miriam and Landrin, Valentine and Leitner, Theo and Merz, Maximilian and von Metzler, Ivana and Michel, Christian S and Müller-Tidow, Carsten and Theurich, Sebastian and Trautmann-Grill, Karolin and Wäsch, Ralph and Zukovs, Romans and Hänel, Mathias and Rasche, Leo and Raab, Marc S},
  title = {A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma},
  journal = {HemaSphere},
  year = {2025},
  volume = {9},
  number = {4},
  doi = {10.1002/hem3.70114}
}
Kostenlos starten →